glp-1 for metabolic syndrome Why are agonists being used to treat patients with nonalcoholic fatty liver disease? glp-1_analogs [TUSOM | Pharmwiki]

The commercial implications of the GLP-1 revolution extend far beyond individual prescribing decisions to encompass fundamental questions about sustainable pricing models, payer coverage strategies, direct-to-consumer marketing approaches, and the long-term market dynamics as biosimilars and new entrants reshape the competitive landscape

Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats

Health at every size [archived link] is one approach suggested for making healthcare more inclusive

Independent Wellness is built around provider-led care rather than low-touch prescription fulfillment